JAMA Neurology: Comparison of 8 plasma amyloid Aβ42/40 detection methods in patients with Alzheimer's disease

The LOOD test to detect the pathology of amyloid (Aβ) in Alzheimer's disease (AD) will be a major advancement in the implementation of biomarkers in clinical treatment, and is very useful in drug trials
.

Reliable measurement of Aβ in blood proved to be challenging until the development of advanced mass spectrometry and immunoassay methods

The LOOD test to detect the pathology of amyloid (Aβ) in Alzheimer's disease (AD) will be a major advancement in the implementation of biomarkers in clinical treatment, and is very useful in drug trials

This study included 182 BIOFINDER cohort participants with normal cognition and 104 patients with mild cognitive impairment.
They were registered in 3 different hospitals in Sweden and received beta positron emission tomography from 2010 to 2014 .
Cerebrospinal fluid and plasma collection
.

This study included 182 BIOFINDER cohort participants with normal cognition and 104 patients with mild cognitive impairment.
They were registered in 3 different hospitals in Sweden and received beta positron emission tomography from 2010 to 2014 .
Cerebrospinal fluid and plasma collection
.

β positron emission tomography, cerebrospinal fluid and plasma collection β positron emission tomography, cerebrospinal fluid and plasma collection

Using the immunoprecipitation coupled mass spectrometry (IP-MS-WASU) developed by the University of Washington, the antibody-free liquid chromatography mass spectrometry (LC-MS-ARC) developed by Araclon, Roche Diagnostics (IA-ELC), European Immunology Corporation ( The immunoassay (IA-N4PE) of IA-EI), Amsterdam University Medical Center, ADX Neuroscience Company and Quanterix Company measures plasma Aβ42/40
.

Using Shimadzu’s IP-MS method (IP-MS-SHIM), the University of Gothenburg’s IP-MS-UGOT method (IP-MS-UGOT) and Quanterix’s immunoassay method (IA-Quan), the measurements were performed respectively.

Using the immunoprecipitation coupled mass spectrometry (IP-MS-WASU) developed by the University of Washington, the antibody-free liquid chromatography mass spectrometry (LC-MS-ARC) developed by Araclon, Roche Diagnostics (IA-ELC), European Immunology Corporation ( IA-EI), Amsterdam University Medical Center, ADX Neuroscience and Quanterix Immunoassay (IA-N4PE) to measure plasma Aβ42/40

For verification, 12 participants from the Alzheimer's Disease Neuroimaging Program (51 with normal cognition, 51 with mild cognitive impairment, and 20 with AD dementia) underwent Aβ-PET and plasma Aβ assessments, using IP- MS-WASU, IP-MS-SHIM, IP-MS-UGOT, IA-ELC, IA-N4PE and IA-Quan analysis

      8 different methods to quantitatively detect the accuracy of plasma A-β42/40 in distinguishing abnormal cerebrospinal fluid A-β42/40 and A-β-PET42/40 status

• A total of 408 participants participated in this study
  .
  
• In the BioFINDER cohort, the mean age (SD) was 71.
  6 (5.
  6) years, of which 49.
  3% were women
  .
  
• The accuracy of plasma IP-MS-WASU Aβ42/40 and LC-MS-Arc Aβ42/40, IA-EI Aβ42/40 and IA-N4PE Aβ42/40 (area under the receiver operating characteristic curve are 0.
  86 and 0.
  81~ 0.
  90), the difference was statistically significant (P<0.
  05)
  .
  
• Plasma IP-MS-WASU Aβ42/40 was significantly better than IP-MS-UGOT Aβ42/40 and IA-QUAβ42/40 (AUC0.
  84vs0.
  68 and 0.
  64; P<0.
  001), while IP-MS-WASU Aβ42/40 and There was no significant difference in AUC of IP-MS-Shim Aβ42/40 (0.
  87vs0.
  83; P=0.
  16)
  .
  
• When using Aβ-PET as the result, the result is similar
  .
  
• Plasma IPMS-WASU Aβ42/40 and IPMS-Shim Aβ42/40 have the highest correlation coefficients with CSF Aβ42/40 (r=0.
  56~0.
  65)
  .
  
• The results of BioFINDER were replicated in the Alzheimer’s Disease Neuroimaging Initiative Cohort (mean [SD] age, 72.
  4 [5.
  4] years; 43.
  4% of women), and the performance of IP-MS-WASU was significantly better than IP- MS-UGOT, IA-ELC, IA-N4PE and IA-Quan test, but IP-MS-Shim test does not
  .
  

A total of 408 participants participated in this study
.

A total of 408 participants participated in this study
.

In the BioFINDER cohort, the mean age (SD) was 71.

The results of two independent cohorts indicate that certain MS-based methods perform better than most plasma Aβ42/40 immunoassay methods in detecting brain Aβ pathology

Literature source: https://jamanetwork-com.
washington.
80599.
net/journals/jamaneurology/fullarticle/2784411 https://jamanetwork-com.
washington.
80599.
net/journals/jamaneurology/fullarticle/2784411 Leave a message here